Medical genome doctrine

Meaning and legal nature

The Medical Genome Doctrine is an emerging legal framework governing the collection, analysis, interpretation, storage, disclosure, and clinical use of a person's genomic information in medicine. It is not presently recognized as a single, universally established legal doctrine. Instead, it draws upon constitutional privacy, bodily autonomy, informed consent, medical negligence, genetic discrimination, biotechnology regulation, and intellectual-property principles.

The importance of the doctrine has increased with genomic sequencing, precision medicine, pharmacogenomics, hereditary-disease testing, cancer genomics, reproductive genetics, and AI-assisted genomic diagnosis.

A person's genome can reveal information not only about present health but also about possible future diseases and biological relationships. Consequently, genomic information has an unusually significant legal character.

Genomic information as sensitive medical information

A genome is different from an ordinary medical record because it can contain information extending beyond one particular medical episode. It may reveal susceptibility to hereditary diseases, possible treatment responses, and information concerning biological relatives.

The Supreme Court's decision in Justice K.S. Puttaswamy (Retd.) v Union of India (2017) provides an important constitutional foundation. The Court recognized privacy as a fundamental right encompassing bodily integrity, decisional autonomy, and informational privacy.

Applied to genomic medicine, this supports the principle that genomic information should not be collected, processed, or disclosed without an appropriate legal and medical justification.

The genomic data lifecycle can therefore be understood as:

Collection → Sequencing → Interpretation → Storage → Clinical use → Sharing → Retention → Deletion

Each stage creates distinct accountability obligations.

Informed consent for genomic testing

Genomic testing can reveal information that a patient did not initially expect to receive. For example, a test ordered for one condition may identify an unrelated hereditary risk.

The principle of informed consent is therefore central.

In Montgomery v Lanarkshire Health Board (2015), the UK Supreme Court emphasized the importance of providing patients with material information relevant to medical decisions.

Applied to genomic medicine, meaningful consent may require explaining:

• the purpose of the genetic test;
• what categories of information may be identified;
• possible incidental findings;
• whether relatives may be affected by the information;
• how long genomic data will be retained;
• whether the information will be used for research; and
• whether it may be shared with third parties.

Consent should therefore address the reasonably foreseeable consequences of genomic testing rather than merely the act of taking a biological sample.

Bodily autonomy and genetic decision-making

Genomic medicine directly engages bodily autonomy. Genetic testing may influence decisions concerning reproduction, preventive treatment, cancer management, or hereditary disease.

Suchita Srivastava v Chandigarh Administration (2009) recognized reproductive autonomy as an important aspect of personal liberty under Article 21. While the case did not concern genomic medicine directly, its reasoning is relevant where genetic information affects reproductive decisions.

Similarly, Common Cause v Union of India (2018) illustrates the constitutional significance of autonomy and dignity in deeply personal medical decisions.

These principles support the proposition that genomic information should generally empower patients to make informed choices rather than become an instrument for coercive medical decision-making.

Genetic information and family privacy

One of the distinctive legal characteristics of genomic information is that it can have implications for biological relatives.

A patient's genetic result may indicate that relatives have an increased likelihood of carrying the same genetic variant. This creates a tension between:

individual confidentiality and potential medical interests of relatives.

Medical professionals may therefore face difficult questions about whether and when genetic information can be disclosed to family members.

There is no universal rule allowing unrestricted disclosure. Confidentiality, patient consent, medical necessity, applicable law, and the seriousness of the foreseeable risk must all be considered.

The principle of informational privacy under Puttaswamy is particularly relevant.

Genetic discrimination

Genomic information can potentially be misused to classify individuals according to predicted health risks.

For example, employers, insurers, or other institutions might attempt to use genetic information to estimate future illness. Such practices raise equality, privacy, and dignity concerns.

Article 14 of the Indian Constitution provides a framework against arbitrary and unreasonable classifications by the State. Where government decisions rely upon genomic characteristics, the classification must have a legitimate objective and rational connection to that objective.

Genomic information should not automatically be treated as a reliable prediction of an individual's future health. Genetic susceptibility is often probabilistic rather than deterministic.

Medical negligence and genomic interpretation

Genomic sequencing does not automatically produce a complete medical diagnosis. Interpretation requires appropriate scientific knowledge, validated databases, clinical context, and professional judgment.

The principles in Bolam v Friern Hospital Management Committee (1957) and Bolitho v City and Hackney Health Authority (1997) are relevant by analogy.

A doctor may potentially face liability where a clinically significant genomic result is ignored, misinterpreted, or communicated in a manner inconsistent with accepted and logically defensible medical practice.

Similarly, laboratories may face responsibility for inaccurate testing, contamination, defective procedures, or incorrect reporting.

The accountability chain may therefore involve:

Testing laboratory → Sequencing platform → Genomic database/software → Genetic counsellor → Physician → Hospital

Determining liability requires identifying where the error occurred and whether it caused foreseeable harm.

Genomic data and artificial intelligence

AI increasingly assists with genomic interpretation. Algorithms may identify genetic variants, estimate disease risk, or recommend possible treatment strategies.

This creates additional accountability concerns because AI systems can produce incorrect or biased interpretations.

A responsible framework should require:

• validation of genomic algorithms;
• appropriate clinical datasets;
• documentation of limitations;
• human review;
• auditability;
• protection against unauthorized genomic-data access; and
• procedures for correcting erroneous interpretations.

An AI-generated genetic risk score should therefore not automatically become a medical fact.

Genomic research and secondary use

Genomic databases have significant scientific value. Researchers may use genomic information to study diseases, develop medicines, and identify therapeutic targets.

However, research use may differ from the purpose for which the original sample was collected.

A patient who consented to diagnostic testing may not necessarily have consented to every future research use. Governance should therefore distinguish between:

clinical use → research use → commercial use → data sharing

Where secondary use is permitted, appropriate consent, anonymization or other privacy safeguards, institutional review, and legal authority should be considered.

Intellectual property and the genome

Genomic medicine also raises intellectual-property questions.

The US Supreme Court's decision in Association for Molecular Pathology v Myriad Genetics (2013) held that naturally occurring DNA is not patentable merely because it has been isolated, while synthetic DNA and certain human-created inventions may receive patent protection.

The decision is significant because it reinforces an important distinction between:

naturally occurring biological information and human-created technological inventions.

A medical genome doctrine should therefore avoid treating the human genome itself as ordinary commercial property.

At the same time, legitimate inventions involving genomic technologies, diagnostic platforms, engineered biological materials, or therapeutic applications may receive protection according to applicable patent law.

Genome modification and medical treatment

The doctrine becomes particularly important where medicine moves from reading the genome to altering it.

Genetic testing and sequencing generally involve observation and analysis. Gene therapy and genome editing involve intervention.

This distinction is legally significant because interventions may create risks affecting not only the patient but potentially future generations where germline modifications are involved.

Existing constitutional principles concerning bodily autonomy, informed consent, and medical safety become particularly important in evaluating such interventions.

Constitutional regulation of compulsory genomic testing

Compulsory genomic testing creates stronger constitutional concerns.

Under the reasoning of Puttaswamy, interference with privacy requires an appropriate legal foundation, legitimate objective, proportionality, and safeguards.

Selvi v State of Karnataka (2010) is also relevant by analogy because the Supreme Court considered the constitutional implications of involuntary techniques used to obtain highly personal information.

Therefore, compulsory genomic testing by the State should not be treated as constitutionally permissible merely because genomic information might be useful. Authorities should establish why testing is necessary, whether less intrusive alternatives exist, who will access the data, how long it will be retained, and what safeguards exist against misuse.

Governance principles

A comprehensive Medical Genome Doctrine should incorporate:

1. Informed consent for significant genomic testing.
2. Purpose limitation restricting genomic information to legitimate purposes.
3. Data minimization and secure storage.
4. Clinical validation of genomic interpretations.
5. Professional accountability for medical decisions.
6. Protection against genetic discrimination.
7. Strict controls on secondary use.
8. Family-related confidentiality safeguards.
9. Cybersecurity and breach reporting.
10. Human oversight of AI-based genomic interpretation.
11. Independent ethical review for research.
12. Effective remedies for misuse or erroneous genomic decisions.

Case-law foundation

The principal jurisprudential foundations can be summarized as follows:

These cases do not collectively establish a formally named "Medical Genome Doctrine." Rather, they provide principles from which such a doctrine can be developed.

Conclusion

The Medical Genome Doctrine seeks to establish legal safeguards for the responsible use of genomic information in healthcare. Its principal concerns are privacy, informed consent, autonomy, scientific reliability, family interests, discrimination, medical negligence, research governance, AI interpretation, and genetic intervention.

The most important principle is that a person's genome should not be treated merely as ordinary medical data or as unrestricted commercial information. It is deeply connected with bodily identity, health, family relationships, and personal autonomy.

As precision medicine expands, the law will increasingly need to ensure that genomic information is collected for legitimate purposes, interpreted scientifically, protected securely, and used in ways consistent with dignity, autonomy, equality, and accountable medical practice.